A Study of YL202 in Selected Patients With Advanced Solid Tumors

NCT06107686 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
Breast Cancer
HNSCC
Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG: YL202 should be intravenously infused

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.